Latest / Breastcancer.org Podcast

Enhertu for HER2-Low Breast Cancer
At the recent 2022 American Society of Clinical Oncology Annual Meeting, researchers presented results showing Enhertu (chemical name: fam-trastuzumab-deruxtecan-nxki), which is a type of medicine doctors call an antibody-drug conjugate, improved both progression-free survival and overall survival in people diagnosed with previously treated metastatic HER2-low breast cancer.
Listen to the podcast to hear Dr. Wojciechowski explain:
what HER2-low breast cancer is
how Enhertu works
how the results of the DESTINY-Breast-04 study will change practice
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.